These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2010-019665-28 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SEQUENTIAL DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACODYNAMICS AND PHARMACOKINETICS OF SINGLE SUBCUTANEOUS DOSES OF HM11260C IN ADULT PA... 2011-04-22 due-trials
Reported results 2011-001826-61 A phase II, randomized, active controlled, open label study of safety and efficacy of HM10560A a Long-acting rhGH-HMC001 conjugate in treatment of subjects suffering from adult growth hormone deficien... 2015-06-29 due-trials
Reported results 2013-003625-29 A Phase II, 12-week, double-blind, randomised, parallel group, multi-centre, international trial to assess the effect on glycaemic control of five doses of HM11260C versus placebo or open-label liragl... 2015-01-27 due-trials
Reported results 2013-004250-13 A Phase II, 16-week, double-blind, placebo-controlled, parallel-group, randomised, multicentre trial to assess effect on glycaemic control of three doses of HM11260C in subjects with inadequately cont... 2015-04-30 due-trials
Reported results 2013-004251-21 A 20-week, double blind, randomized, placebo controlled, parallel group trial to assess the safety and efficacy of HM11260C on body weight in obese subjects without diabetes. 2015-02-17 due-trials
Not reported 2015-001435-21 A single-arm, open-label, Phase 2 study evaluating the efficacy, safety and pharmacokinetics of HM61713 (BI 1482694) in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment ... 2020-03-18 due-trials
Listed as ongoing, but also has a completion date and reported results 2016-001857-42 A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr... 2020-09-07 bad-data
Other 2021-000176-11 A Multicenter, Proof-of-concept, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15912 in Adult Subjects with Short Bowel Syndrome-associated Intestinal... not-yet-due
Other 2021-000508-39 A Phase 2, Multiple Ascending Dose, Open-label, Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years W... not-yet-due